NCT02530489 2026-02-17
Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
Clinical Trials
63 trialsNCT02999477 2026-01-29
A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
NCT04148911 2025-12-26
EL1SSAR
Hoffmann-La Roche
Phase 3 Completed
NCT02514681 2025-09-10
PRECIOUS
Japan Breast Cancer Research Group
Phase 3 Completed
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT03554044 2025-05-21
T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer
University of California, San Francisco
Phase 1 Completed
NCT01818063 2025-04-30
Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer
Thomas Jefferson University
Phase 2 Completed
NCT03950570 2024-12-31
ORIN1001 in Patients with Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer
Orinove, Inc.
Phase 1/2 Completed
NCT02819518 2024-11-27
KEYNOTE-355
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01822314 2024-03-07
ETNA
Fondazione Michelangelo
Phase 3 Completed
NCT03121352 2023-10-06
Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT03112590 2023-04-19
Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT01036087 2023-03-30
Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01565499 2023-03-30
Neoadjuvant Treatment With Nab-paclitaxel for Patients With Stage II and III Luminal Breast Cancer
Spanish Breast Cancer Research Group
Phase 2 Completed
NCT04584112 2023-03-15
A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer
Hoffmann-La Roche
Phase 1 Completed
NCT01446016 2023-01-23
CAT
The Methodist Hospital Research Institute
Phase 2 Completed
NCT02762981 2022-12-06
Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors
Corcept Therapeutics
Phase 1/2 Completed
NCT00785291 2022-10-10
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT02425891 2022-07-19
A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)
Hoffmann-La Roche
Phase 3 Completed
NCT02379247 2022-06-07
BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer
University of Kansas Medical Center
Phase 1/2 Completed
NCT03166085 2021-12-20
PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00629499 2021-11-24
Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00193206 2021-11-23
Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT01847001 2021-09-10
Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
Columbia University
Phase 2 Completed
NCT00723125 2021-04-29
Carboplatin, Abraxane, Avastin as Neoadjuvant Therapy for Her2-Negative Breast Cancer
Brown University
Phase 2 Completed
NCT03289819 2021-04-08
NIB
Institut fuer Frauengesundheit
Phase 2 Completed
NCT02687490 2021-03-01
Abraxane in Patients With Visceral Metastases Dominant Metastatic Breast Cancer
Fudan University
Phase 2 Completed
NCT02682693 2021-02-02
GeparX
GBG Forschungs GmbH
Phase 2 Completed
NCT00442260 2021-01-22
Doxorubicin HCL Liposome Injection (DOXIL) in Combination With Abraxane in Patients With Metastatic Breast Cancer
West Virginia University
Phase 1/2 Completed
NCT01583426 2020-08-06
GeparSepto
GBG Forschungs GmbH
Phase 3 Completed
NCT00331630 2020-03-06
Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
Northwestern University
Phase EARLY_PHASE1 Completed
NCT00093145 2019-11-25
Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer
Celgene
Phase 2 Completed
NCT00394082 2019-11-25
ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer
Celgene
Phase 2 Completed
NCT00394251 2019-11-25
Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer
Celgene
Phase 2 Completed
NCT00274456 2019-11-21
Phase II Trial Comparing ABI-007 (Abraxane®, Nab®-Paclitaxel) to Taxotere in First Line Therapy of Patients With Stage IV Breast Cancer
Celgene
Phase 2 Completed
NCT03505528 2019-11-13
Epi-PRIMED
EpiAxis Therapeutics
Phase 1 Completed
NCT02309177 2019-05-31
Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer
Celgene
Phase 1 Completed
NCT02073916 2019-04-16
STELA
The Methodist Hospital Research Institute
Phase 1 Completed
NCT00254592 2019-02-28
Neoadjuvant Treatment of Breast Cancer
University of California, Irvine
Phase 2 Completed
NCT01881230 2019-02-21
tnAcity
Celgene
Phase 2/3 Completed
NCT00733408 2018-12-04
Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer
University of Washington
Phase 2 Completed
NCT01973660 2018-09-19
PAMELA
SOLTI Breast Cancer Research Group
Phase 2 Completed
NCT01493310 2018-09-12
Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer
University of Chicago
Phase 1 Completed
NCT00915018 2018-08-22
NEFERTT
Puma Biotechnology, Inc.
Phase 2 Completed
NCT00944047 2018-04-23
Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression
University of Kansas Medical Center
Phase 2 Completed
NCT02783222 2018-01-10
EFFECT
Fondazione Sandro Pitigliani
Phase 2 Completed
NCT01307891 2017-10-26
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
University of Alabama at Birmingham
Phase 2 Completed
NCT00654836 2017-09-14
Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
Loyola University
Phase 2 Completed
NCT00407888 2017-08-31
Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Trastuzumab in Treating Patients With Breast Cancer Previously Treated With Surgery
University of Washington
Phase 2 Completed
NCT00748553 2017-07-26
VA
University of Utah
Phase 1/2 Completed